Back to top
more

Werewolf Therapeutics (HOWL)

(Delayed Data from NSDQ)

$1.18 USD

1.18
65,298

-0.01 (-0.84%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $1.18 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

New Strong Buy Stocks for January 20th

by Zacks Equity Research

NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.

Zacks Equity Research

New Strong Buy Stocks for January 18th

by Zacks Equity Research

DTEGY, CYN, OKTA, HOWL and ONCY have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.

Zacks Equity Research

Werewolf Therapeutics, Inc. (HOWL) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.33% and 18.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Consider Investing in JAZZ Stock Now

by Zacks Equity Research

JAZZ's new drugs like Xywav, Rylaze and Zepzelca, along with the recently-acquired drugs, are expected to generate 65% of product revenues in 2022.

Zacks Equity Research

JAZZ's Late-Stage Multiple Sclerosis Study on Nabiximols Fails

by Zacks Equity Research

JAZZ's phase III study evaluating nabiximols oromucosal spray for clinical measures of spasticity in multiple sclerosis patients fails to meet the primary endpoint.

Zacks Equity Research

JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?

by Zacks Equity Research

Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.

Zacks Equity Research

JAZZ Inks Deal With Werewolf to Add Oncology Candidate

by Zacks Equity Research

Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.

Zacks Equity Research

Werewolf (HOWL) Up on Deal With Merck for Solid Tumor Study

by Zacks Equity Research

Werewolf Therapeutics (HOWL) inks a collaboration and supply agreement with Merck to evaluate its candidate, WTX-124, in combination with Keytruda, for treating solid tumors. Stock up.